Indications for DIFLUCAN 150mg:
150mg orally once.
Concomitant terfenadine at multiple doses of fluconazole ≥400mg. Concomitant drugs known to prolong the QT interval and metabolized by CYP3A4 (eg, cisapride, astemizole, erythromycin, pimozide, quinidine).
Risk of serious hepatotoxicity; monitor liver function during therapy and for signs/symptoms of hepatic injury; discontinue if occurs. Proarrhythmic conditions. Monitor closely for skin rashes; discontinue if lesions progress. Allergy to other azoles. Renal or hepatic impairment. Elderly. Pregnancy (avoid); may cause rare congenital anomalies in infants exposed in-utero during 1st trimester. Nursing mothers.
See Contraindications. Avoid concomitant voriconazole; if needed, monitor closely esp. when given within 24hrs after fluconazole. Caution with amiodarone (esp. with high-dose fluconazole), other drugs metabolized by CYP2C9 and CYP3A4 with a narrow therapeutic window. Potentiates warfarin, sulfonylureas, oral midazolam, triazolam, tofacitinib, alfentanil, amitriptyline, nortriptyline, saquinavir, tacrolimus, sirolimus, carbamazepine, methadone, NSAIDs, zidovudine; adjust dose as necessary. May increase levels of phenytoin, theophylline, halofantrine, rifabutin, vinca alkaloids, cyclosporine, fentanyl, CCBs, losartan; monitor. Concomitant celecoxib: reduce celecoxib dose by half. Increased risk of myopathy/rhabdomyolysis with concomitant HMG-CoA reductase inhibitors; closely monitor. Avoid concomitant olaparib; reduce its dose if unavoidable. May be potentiated by diuretics. May be antagonized by oral cimetidine, rifampin. Concomitant prednisone: monitor for adrenal cortex insufficiency when fluconazole stopped. CNS effects with Vitamin A. Oral contraceptives: see full labeling. Avoid other hepatotoxic drugs.
Nausea, headache, rash, vomiting, abdominal pain, diarrhea, dizziness; hepatotoxicity, adrenal insufficiency; rare: anaphylaxis, exfoliative dermatitis, QT prolongation, Torsade de pointes.